If not, pay out-of-pocket, its worth it
Despite the encouraging results of GLP-1/glucagon co-agonism in experimental models, different GLP-1 and glucagon co-agonists have shown various levels of efficacy and tolerability in people with obesity and/or T2D, in early phase clinical trials, which may be explained by the different ratio of GLP-1 to glucagon activity between the different molecules [65]
Neuroendocrinology Letters, 2011, PMID: 11335874) Results of 12-months treatment with Epithalon in patients with signs of accelerated aging showed normalizing effect on metabolism and condition of various functional systems
Instead, they are determining whether regulated compounding pharmacies should be legally allowed to manufacture and prepare bulk BPC 157 at all due to potential safety risks
For injury healing protocols, refer to the Injury Protocols guide to design the appropriate stack